Latest Conference Articles

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Nearly half of evaluable patients with rare central nervous system tumors, neuroblastoma, or other solid tumors had responses to entrectinib.

Lowest test dose of oxaliplatin and capecitabine was comparable to the highest dose in delaying advanced gastroesophageal cancer progression and minimizing adverse effects.

Lenalidomide found to prevent the formation of blood vessels that feed tumors, yet carries significant adverse effects.

Matthew Pickering, PharmD, RPh, PQA Senior Director of Research & Quality Strategies at Pharmacy Quality Alliance discusses what pharmacists bring to patient care in the Pharmacy Quality Alliance Annual Meeting in Baltimore, MD.

Matthew Pickering, PharmD, RPh, PQA Senior Director of Research & Quality Strategies at Pharmacy Quality Alliance discusses its medication access framework for quality measurement during the Pharmacy Quality Alliance Annual Meeting in Baltimore, MD.

National Cancer Institute-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice is the first nationwide precision oncology trail for patients with cancers that have not responded to standard treatments.

Laura Cranston, RpH, CEO of Pharmacy Quality Alliance (PQA), discusses the organization's origins as a measure developer during the PQA Annual Meeting in Baltimore, MD.

Lisa Hines, PharmD, vice president of Measurement and Operations at Pharmacy Quality Alliance (PQA), discusses PQA's new opioid measures and how they complement existing measures during the Pharmacy Quality Alliance Annual Meeting in Baltimore, MD.

Norris Turner, PharmD, PhD, vice president of Strategic Alliances and Measures at PQA discusses the uses of PQA's measures in Medicaid during the Pharmacy Quality Alliance Annual Meeting in Baltimore, MD.

Matt Farber, MA, Senior Director of Patient Care and Advocacy at Walgreens discusses some of the ways that Walgreens is advancing care for patients with cancer.

Matt Farber, MA, Senior Director of Patient Care and Advocacy at Walgreens, talks about the growing role of specialty pharmacies in delivering cancer care.

It was during the middle of the night when Suzanne Soliman, PharmD, founder of the Pharmacist Mom Group on Facebook, got the idea for her group page, which has since grown to be one of the most active on the popular social media platform, with more than 2 million posts last year alone.

At the Asembia Specialty Pharmacy Summit 2019, Matt Farber, MA, Senior Director of Patient Care and Advocacy at Walgreens discussed top trends in specialty pharmacy that are likely to continue to impact the industry.

During the featured session at Asembia’s Specialty Pharmacy Summit 2019, “Specialty Industry Outlook: What’s Next,” speakers Adam Fein, PhD, CEO of the Drug Channels Institute; Lisa Gill, managing director of J.P. Morgan Securities; and Doug Long, vice president of industry relations at IQVIA, explored the radical changes that could be on the horizon from potential legislation that would dramatically alter the health care industry.

Matt Farber, MA, Senior Director of Patient Care and Advocacy at Walgreens provided insight into new areas of technology that pharmacists can use to help improve care when treating patients with cancer.

Matt Farber, MA, Senior Director of Patient Care and Advocacy at Walgreens, discussed the role of specialty pharmacists in working to manage the cost burden of cancer care.

Since the growth of specialty pharmacies, genetically acquired bleeding disorders such as von Willebrand disease (VWD) have been among the most common conditions addressed at these practice locations.

At the Asembia Specialty Pharmacy Summit 2019, Scott Gottlieb, MD, 23rd commissioner of the FDA discussed the agency's role in rewriting the modern rules of new regulatory paradigms for a number of recent advancements in medicine.

Most Americans have never heard of hereditary transthyretin amyloidosis (hATTR), which speaks to its very low incidence rate in the population.

The oncology drug pipeline has experienced rapid growth over the past decade, driven by innovation in cell therapies, immunotherapy, and precision medicine, according to a specialty pipeline update presentation at the Asembia Specialty Pharmacy Summit 2019.

Co-pay accumulator programs are the latest cost management initiative resulting from the constant push and pull between payers, pharmacy benefit managers, and manufacturers to reduce drug spend.

Treatment for inflammatory bowel disease has the best outcomes when patients partner with their medical teams.

Why health system specialty pharmacies are uniquely positioned to provide valuable data and superior care to the patients they serve.

The specialty lite platform leverages the current infrastructure of specialty pharmacies with efficient services and emerging technological solutions that focus on ensuring prescription fulfillment with economic feasibility.

Experts emphasized the need for clinicians to use every available tool when patients need PCSK9 inhibitors but face access barriers.

During a session on Monday at Asembia’s Specialty Pharmacy Summit 2019, experts discussed specialty pharmacy’s potential to improve outcomes for patients with pulmonary arterial hypertension.

Diagnostic delay tends to be a challenge for patients with hereditary angioedema, a rare but serious condition affecting 1 in 50,000 individuals.